JP2019501190A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501190A5
JP2019501190A5 JP2018535278A JP2018535278A JP2019501190A5 JP 2019501190 A5 JP2019501190 A5 JP 2019501190A5 JP 2018535278 A JP2018535278 A JP 2018535278A JP 2018535278 A JP2018535278 A JP 2018535278A JP 2019501190 A5 JP2019501190 A5 JP 2019501190A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
dgla
derivative
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000066 external-priority patent/WO2017118911A1/en
Publication of JP2019501190A publication Critical patent/JP2019501190A/ja
Publication of JP2019501190A5 publication Critical patent/JP2019501190A5/ja
Pending legal-status Critical Current

Links

Images

JP2018535278A 2016-01-07 2017-01-06 Dglaを含む薬学的組成物及びその使用 Pending JP2019501190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276019P 2016-01-07 2016-01-07
US62/276,019 2016-01-07
US201662357000P 2016-06-30 2016-06-30
US62/357,000 2016-06-30
PCT/IB2017/000066 WO2017118911A1 (en) 2016-01-07 2017-01-06 Pharmaceutical compositions comprising dgla and use of same

Publications (2)

Publication Number Publication Date
JP2019501190A JP2019501190A (ja) 2019-01-17
JP2019501190A5 true JP2019501190A5 (https=) 2020-02-13

Family

ID=58213263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535278A Pending JP2019501190A (ja) 2016-01-07 2017-01-06 Dglaを含む薬学的組成物及びその使用

Country Status (6)

Country Link
US (2) US20170196825A1 (https=)
EP (1) EP3399971A1 (https=)
JP (1) JP2019501190A (https=)
CN (1) CN108778266A (https=)
CA (1) CA3027867A1 (https=)
WO (1) WO2017118911A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
ES2784240T3 (es) 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3624787A1 (en) * 2017-05-19 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
WO2006085687A1 (ja) * 2005-02-14 2006-08-17 Suntory Limited ジホモ−γ−リノレン酸(DGLA)を有効成分として含んで成る組成物
JP5546087B2 (ja) * 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
ES2784240T3 (es) * 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas

Similar Documents

Publication Publication Date Title
JP2019501190A5 (https=)
Wisłowska et al. Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease
JP2017516823A5 (https=)
Koch et al. Ten year follow-up of forty patients with the midsystolic click/late systolic murmur syndrome
RU2016151719A (ru) Фармацевтические композиции, содержащие дглк, и их применение
Sims et al. Comparison of findings in patients with versus without atrial fibrillation just before isolated mitral valve replacement for rheumatic mitral stenosis (with or without associated mitral regurgitation)
Panja et al. Cardiac involvement in non-specific aorto-arteritis
Gould et al. Cardiac manifestations of ochronosis
Iqbal et al. Stroke after coronary artery bypass surgery with and without cardiopulmonary bypass
Hanbury Calcified cardiac aneurysm
Flores et al. Rheumatoid Arthritis with severe Aortic lnsufficiency and Prolapse of the Mitral Valve
Liu et al. Catheter ablation of ventricular arrhythmias originating from the pulmonary sinus cusp in pediatric patients: a single-center retrospective study
Klein et al. 99mTc (Sn) pyrophosphate scintigrams in exercise-induced angina and calcified valves
Ashcheulova et al. ECG signs of hypertrophy of heart atriums and ventricles
Barth et al. Amyloid Coronary Artery Disease, Primary Systemic Amyloidosis and Paraproteinemia
Omoto et al. Left atrial thrombus in a patient without mitral valve disease or atrial fibrillation
Ristić-Andjelkov et al. Left ventricular noncompaction in a patient presenting with a left ventricular failure
Kouchoukos et al. Surgical treatment of unstable angina pectoris: Results in 65 patients
Khullar et al. Mitral valve prolapse syndrome (MVPS): Left ventricular function and myocardial metabolism
Yamada et al. P4741 Plasma volume status provides the additional long-term prognostic information to ADHERE risk level in patients admitted for acute decompensated heart failure
Cîrneală et al. Coronary Artery Aneurysms Due to Kawasaki Disease–a Rare Cause of Acute Myocardial Infarction
Ueshima et al. What determines the heart rate response to exercise in patients with atrial fibrillation?
Diuvenji et al. Thyrotoxic cardiomyopathy: a case report
Freriks et al. PO-04-222 THE IMPACT OF ATRIAL DILATATION ON CONDUCTION HETEROGENEITY AT BACHMANN'S BUNDLE
Parsaie et al. Long-term Follow-up of Cardiac Calcified Amorphous Tumor in Three Thalassemia Patients